Literature DB >> 12450762

Atopy, helminths, and cancer.

Brad E Zacharia1, Brad Zacharia, Paul Sherman.   

Abstract

There are two hypotheses for the primary function of the T(H)/IgE system: protection against helminths that 'spills over' into inappropriate allergic responses in the modern environment, or protection from a variety of environmental carcinogens and infectious diseases that is adaptive even today. We suggest that rather than being alternatives, these two hypotheses fit into a single causal framework. Atopic responses to helminths kill, inhibit, or expel the parasites, thereby reducing their debilitating effects, the most serious of which is bladder cancer. The ultimate (evolutionary) reason for the T(H)2/IgE system may be minimizing chances that multiple biotic and abiotic hazards and carcinogens will enter the body; in some tropical areas, helminths are the major proximate (immediate) triggers of this response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12450762     DOI: 10.1016/s0306-9877(02)00217-7

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  10 in total

1.  [Bone marrow hematopoiesis. Evaluation of the myelogram].

Authors:  E B Vladimirskaia
Journal:  Gematol Transfuziol       Date:  1990-08       Impact factor: 0.172

2.  Allergic host defences.

Authors:  Noah W Palm; Rachel K Rosenstein; Ruslan Medzhitov
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

3.  Asthma status is associated with decreased risk of aggressive urothelial bladder cancer.

Authors:  Marta Rava; Maciej J Czachorowski; Debra Silverman; Mirari Márquez; Sirish Kishore; Adonina Tardón; Consol Serra; Montse García-Closas; Reina Garcia-Closas; Alfredo Carrato; Nathaniel Rothman; Francisco X Real; Manolis Kogevinas; Núria Malats
Journal:  Int J Cancer       Date:  2017-10-16       Impact factor: 7.396

4.  Interleukin (IL) 5 levels and eosinophilia in patients with intestinal parasitic diseases.

Authors:  Sebnem Ustun; Nevin Turgay; Songul-Bayram Delibas; Hatice Ertabaklar
Journal:  World J Gastroenterol       Date:  2004-12-15       Impact factor: 5.742

5.  Association between allergies and risk of pancreatic cancer.

Authors:  Michelle Cotterchio; Elizabeth Lowcock; Thomas J Hudson; Celia Greenwood; Steven Gallinger
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-19       Impact factor: 4.254

6.  Human schistosome infection and allergic sensitisation.

Authors:  Nadine Rujeni; David W Taylor; Francisca Mutapi
Journal:  J Parasitol Res       Date:  2012-08-27

7.  High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID).

Authors:  Barry R Zeeberg; Haiying Qin; Sudarshan Narasimhan; Margot Sunshine; Hong Cao; David W Kane; Mark Reimers; Robert M Stephens; David Bryant; Stanley K Burt; Eldad Elnekave; Danielle M Hari; Thomas A Wynn; Charlotte Cunningham-Rundles; Donn M Stewart; David Nelson; John N Weinstein
Journal:  BMC Bioinformatics       Date:  2005-07-05       Impact factor: 3.169

8.  Activated Natural Killer Cells Mediate the Suppressive Effect of Interleukin-4 on Tumor Development via STAT6 Activation in an Atopic Condition Melanoma Model.

Authors:  Dong Ju Son; Yu Yeon Jung; Mi Hee Park; Hye Lim Lee; Min Ji Song; Hwan-Soo Yoo; Dae Youn Hwang; Sang Bae Han; Jin Tae Hong
Journal:  Neoplasia       Date:  2017-06-03       Impact factor: 5.715

9.  Cancer: A disease at the crossroads of trade-offs.

Authors:  Camille Jacqueline; Peter A Biro; Christa Beckmann; Anders Pape Moller; François Renaud; Gabriele Sorci; Aurélie Tasiemski; Beata Ujvari; Frédéric Thomas
Journal:  Evol Appl       Date:  2016-12-26       Impact factor: 5.183

Review 10.  IgE Antibodies: From Structure to Function and Clinical Translation.

Authors:  Brian J Sutton; Anna M Davies; Heather J Bax; Sophia N Karagiannis
Journal:  Antibodies (Basel)       Date:  2019-02-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.